1160415-45-1

1160415-45-1 structure

Name: Bepotastine tosylate
Chemical Name: Bepotastine tosylate
CAS Number: 1160415-45-1
Molecular Formula: C₂₈H₃₃ClN₂O₆S
Molecular Weight: 561.09
Catalog: Signaling Pathways GPCR/G Protein Histamine Receptor
Create Date: 2022-08-11 13:16:17
Modify Date: 2024-01-10 18:45:08
Bepotastine tosylate is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine tosylate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research[1][2][3].

Name	Bepotastine tosylate

Description	Bepotastine tosylate is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine tosylate has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research[1][2][3].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Endocrinology Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
Target	Histamine H1 Receptor[1][2][3].
In Vitro	Bepotastine tosylate (10, 100, 1000 µM; preincubates for 120 minutes) decreases the release of histamine induced by A23187 treatment, which reaches a statistically significant reduces level at 1000 µM[2]. Cell Viability Assay[2] Cell Line: RPMCs cells Concentration: 10, 100, 1000 µM Incubation Time: 120 minutes (preincubate) Result: Decreased the release of histamine.
In Vivo	Bepotastine tosylate (10 g/L (1.0% (w/v)) for 10 µL; 3 times at intervals of 20 minutes in one eye) demonstrates significant inhibition of PAF-induced conjunctival eosinophil infiltration[2]. Bepotastine tosylate (3 mg/kg; p.o.; once) suppresses scratching behavior to a frequency of 59.0 and a duration of 14.57 seconds, which are almost the same levels compares with the control[3]. Bepotastine tosylate (10 mg/kg; p.o.; once) significantly suppresses serum LTB 4 levels to 711.3 pg/mL at 1 hour and 858.8 pg/mL at 2 hours in NC/Nga mice with a rash[3]. Animal Model: Guinea pigs (6-week-old)[2]. Dosage: 10 g/L (1.0% (w/v)) for 10 µL. Administration: 3 times at intervals of 20 minutes (in one eye) Result: Inhibited PAF-induced conjunctival eosinophil infiltration. Animal Model: Male BALB/c mice(12-week-old); NC/Nga mice[3]. Dosage: 3, 10 mg/kg Administration: Oral administration; once (1 hour before induces scratching behavior of Male BALB/c mice). Result: Significantly inhibited histamine-mediated scratching behavior in male BALB/c mice. Significantly suppressed serum LTB 4 levels in NC/Nga mice with a rash.
References	[1]. Jon I Williams, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010 Oct;26(10):2329-38. [2]. Kida T, Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010 Jul;91(1):85-91. [3]. Tanizaki H, Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int Arch Allergy Immunol. 2008;145(4):277-82.

Molecular Formula	C₂₈H₃₃ClN₂O₆S
Molecular Weight	561.09

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1160415-45-1	190730-42-8
1415692-17-9	190786-44-8
190786-43-7	16472-98-3
61-75-6	30716-01-9
1333386-17-6	1187020-80-9
2402789-35-7	2402829-15-4
1427416-71-4	2402789-80-2
2004682-73-7	2402830-14-0
2402830-13-9	2402789-08-4
2402838-43-9	2402789-65-3